The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma

Journal of Ovarian Research

Kyu Yun Jang³  Myoung Jae Kang³  Woo Sung Moon³  Myoung Ja Chung³  Kyoung Min Kim³  See-Hyoung Park²  Ho Sung Park³  Dong Hyu Cho¹ 

[1] Department of Obstetrics and Gynecology, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, Republic of Korea;Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California, USA;Departments of Pathology, Chonbuk National University Medical School, Research Institute of Clinical Medicine and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea

关键词: Prognosis;    BRCA1;    Deleted in breast cancer 1;    Serous carcinoma;    Ovarian neoplasms;   

Others  :  1135921
DOI  :  10.1186/s13048-015-0129-3

【 摘 要 】

Background

Recent reports have shown that deleted in breast cancer 1 (DBC1/CCAR2) is an indicator of poor prognosis of various human cancers. However, its expression in ovarian carcinoma has not been reported.

Methods

We investigated the immunohistochemical expression of DBC1 and BRCA1 and their prognostic significance in 104 ovarian carcinomas. Survival analyses were performed according to the Kaplan-Meier method, as well as univariate and multivariate Cox proportional hazard regression analysis.

Results

Positive expression of DBC1 and BRCA1 were seen in 63% (66/104) and 44% (46/104) of overall ovarian carcinomas, respectively. DBC1 expression was significantly associated with advanced clinicopathological factors such as high tumor stage, latent distant metastasis, platinum-resistance, elevated serum levels of CA125, high histologic grade, and BRCA1 expression. In the histological subtypes of ovarian carcinomas, DBC1 expression was more common in serous carcinoma (72%, 54/75) than mucinous carcinoma (15%, 3/20). BRCA1 expression was significantly associated with latent distant metastasis, platinum-resistance, and higher histologic grade. In addition, DBC1 expression was significantly associated with shorter overall survival (OS) and relapse-free survival (RFS) in 104 ovarian carcinomas (OS; P < 0.001, RFS; P < 0.001) and 63 high-grade serous carcinomas (OS; P = 0.008, RFS; P = 0.023) by univariate analysis. BRCA1 expression was significantly associated with OS and RFS in 104 ovarian carcinomas (OS; P = 0.005, RFS; P = 0.002) and 75 serous carcinomas (OS; P = 0.047, RFS; P = 0.038) by univariate analysis. Moreover, DBC1 expression was an independent prognostic indicator for OS in both 104 ovarian carcinomas (P = 0.021) and 63 high-grade serous carcinomas (P = 0.011) by multivariate analysis.

Conclusions

These results indicate that the expression of DBC1 and BRCA1 are closely related with in the progression of ovarian carcinomas and may have clinical utility in the prediction of prognosis of ovarian carcinomas. Especially, DBC1 expression could be employed as a significant prognostic indicator for ovarian carcinomas especially in high-grade serous carcinomas.

【 授权许可】

   
2015 Cho et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Hamaguchi M, Meth JL, von Klitzing C, Wei W, Esposito D, Rodgers L, et al.: DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci U S A 2002, 99:13647-52.
• [2]Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al.: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Canc Discov 2012, 2:401-4.
• [3]Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al.: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013, 6:11.
• [4]Zhao W, Kruse JP, Tang Y, Jung SY, Qin J, Gu W: Negative regulation of the deacetylase SIRT1 by DBC1. Nature 2008, 451:587-90.
• [5]Kim JE, Chen J, Lou Z: DBC1 is a negative regulator of SIRT1. Nature 2008, 451:583-6.
• [6]Sung JY, Kim R, Kim JE, Lee J: Balance between SIRT1 and DBC1 expression is lost in breast cancer. Cancer Sci 2010, 101:1738-44.
• [7]Kim W, Kim J-E: Deleted in breast cancer 1 (DBC1) deficiency results in apoptosis of breast cancer cells through impaired responses to UV-induced DNA damage. Cancer Lett 2013, 333:180-6.
• [8]Li Z, Chen L, Kabra N, Wang C, Fang J, Chen J: Inhibition of SUV39H1 methyltransferase activity by DBC1. J Biol Chem 2009, 284:10361-6.
• [9]Zhang Y, Gu Y, Sha S, Kong X, Zhu H, Xu B, et al.: DBC1 is over-expressed and associated with poor prognosis in colorectal cancer. Int J Clin Oncol 2014, 19:106-12.
• [10]Bae JS, Park SH, Kim KM, Kwon KS, Kim CY, Lee HK, et al.: CK2alpha phosphorylates DBC1 and is involved in the progression of gastric carcinoma and predicts poor survival of gastric carcinoma patients. Int J Cancer 2015, 136:797-809.
• [11]Park HS, Bae JS, Noh SJ, Kim KM, Lee H, Moon WS, et al.: Expression of DBC1 and androgen receptor predict poor prognosis in diffuse large B cell lymphoma. Transl Oncol 2013, 6:370-81.
• [12]Noh SJ, Kang MJ, Kim KM, Bae JS, Park HS, Moon WS, et al.: Acetylation status of P53 and the expression of DBC1, SIRT1, and androgen receptor are associated with survival in clear cell renal cell carcinoma patients. Pathology 2013, 45:574-80.
• [13]Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Yu TK, et al.: Expression of SIRT1 and DBC1 is associated with poor prognosis of soft tissue sarcomas. PLoS One 2013, 8:e74738.
• [14]Lee H, Kim KR, Noh SJ, Park HS, Kwon KS, Park BH, et al.: Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol 2011, 42:204-13.
• [15]Cha EJ, Noh SJ, Kwon KS, Kim CY, Park BH, Park HS, et al.: Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res 2009, 15:4453-9.
• [16]Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee NR, et al.: SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol 2008, 32:1523-31.
• [17]Park SH, Riley PT, Frisch SM: Regulation of anoikis by deleted in breast cancer-1 (DBC1) through NF-kappaB. Apoptosis 2013, 18:949-62.
• [18]Joshi P, Quach OL, Giguere SS, Cristea IM: A Functional Proteomics Perspective of DBC1 as a Regulator of Transcription. J Proteomics Bioinform 2013, Suppl 2:1-17.
• [19]Chini EN, Chini CC, Nin V, Escande C: Deleted in breast cancer-1 (DBC-1) in the interface between metabolism, aging and cancer. Biosci Rep 2013, 33:e00058.
• [20]Kim SH, Kim JH, Yu EJ, Lee KW, Park CK: The overexpression of DBC1 in esophageal squamous cell carcinoma correlates with poor prognosis. Histol Histopathol 2012, 27:49-58.
• [21]Fu J, Jiang J, Li J, Wang S, Shi G, Feng Q, et al.: Deleted in breast cancer 1, a novel androgen receptor (AR) coactivator that promotes AR DNA-binding activity. J Biol Chem 2009, 284:6832-40.
• [22]Hiraike H, Wada-Hiraike O, Nakagawa S, Koyama S, Miyamoto Y, Sone K, et al.: Identification of DBC1 as a transcriptional repressor for BRCA1. Br J Cancer 2010, 102:1061-7.
• [23]Wiedemeyer WR, Beach JA, Karlan BY: Reversing platinum resistance in high-grade serous ovarian carcinoma: targeting BRCA and the homologous recombination system. Front Oncol 2014, 4:34.
• [24]Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, et al.: Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012, 307:382-9.
• [25]Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-16.
• [26]Kurman RJ: International Agency for Research on Cancer., World Health Organization: WHO classification of tumours of female reproductive organs. 4th edition. International Agency for Research on Cancer, Lyon; 2014.
• [27]Edge S: Cancer AJCo: AJCC cancer staging handbook: From the AJCC cancer staging manual. Springer, New York; 2010.
• [28]Allred D, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998, 11:155-68.
• [29]Noh SJ, Bae JS, Jamiyandorj U, Park HS, Kwon KS, Jung SH, et al.: Expression of nerve growth factor and heme oxygenase-1 predict poor survival of breast carcinoma patients. BMC Cancer 2013, 13:516. BioMed Central Full Text
• [30]Garg K, Levine DA, Olvera N, Dao F, Bisogna M, Secord AA, et al.: BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. Am J Surg Pathol 2013, 37:138-46.
• [31]Mylona E, Melissaris S, Nomikos A, Theohari I, Giannopoulou I, Tzelepis K, et al.: Effect of BRCA1 immunohistochemical localizations on prognosis of patients with sporadic breast carcinomas. Pathol Res Pract 2014, 210:533-40.
• [32]Escande C, Chini CC, Nin V, Dykhouse KM, Novak CM, Levine J, et al.: Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest 2010, 120:545-58.
• [33]Jang KY, Noh SJ, Lehwald N, Tao GZ, Bellovin DI, Park HS, et al.: SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. PLoS One 2012, 7:e45119.
• [34]Menssen A, Hydbring P, Kapelle K, Vervoorts J, Diebold J, Luscher B, et al.: The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci U S A 2012, 109:E187-96.
• [35]Yuan J, Minter-Dykhouse K, Lou Z: A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J Cell Biol 2009, 185:203-11.
• [36]Noguchi A, Kikuchi K, Zheng H, Takahashi H, Miyagi Y, Aoki I, et al.: SIRT1 expression is associated with a poor prognosis, whereas DBC1 is associated with favorable outcomes in gastric cancer. Cancer Med 2014, 3:1553-61.
• [37]Bae HJ, Chang YG, Noh JH, Kim JK, Eun JW, Jung KH, et al.: DBC1 does not function as a negative regulator of SIRT1 in liver cancer. Oncol Lett 2012, 4:873-7.
• [38]Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, et al.: Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology 2009, 41:366-71.
• [39]Hiraike H, Wada-Hiraike O, Nakagawa S, Saji S, Maeda D, Miyamoto Y, et al.: Expression of DBC1 is associated with nuclear grade and HER2 expression in breast cancer. Exp Ther Med 2011, 2:1105-9.
• [40]Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY: Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003, 97:2187-95.
• [41]Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S: Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 2008, 26:20-5.
• [42]Nicum S, Roberts C, Boyle L, Kopijasz S, Gourley C, Hall M, et al.: A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol. BMC Cancer 2014, 14:983.
• [43]Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al.: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-44.
• [44]Tutt A, Robson M, Garber J, Domchek S, Audeh M, Weitzel J, et al.: Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol (Meeting Abstracts) 2009., 27Article ID CRA501
• [45]Edmondson RJ, Monaghan JM, Davies BR: The human ovarian surface epithelium is an androgen responsive tissue. Br J Cancer 2002, 86:879-85.
• [46]Elattar A, Warburton KG, Mukhopadhyay A, Freer RM, Shaheen F, Cross P, et al.: Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. Gynecol Oncol 2012, 124:142-7.